Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation

British Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2002, Pages 386-389

  Cremers, Serge ^a   Schoemaker, Rik ^a   Bredius, Robbert ^a   Den Hartigh, Jan ^a   Ball, Lynne ^a   Twiss, Irene ^a   Vermeij, Pieter ^a   Vossen, Jaak ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Busulfan; Paediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; MYELOABLATIVE AGENT;

ADOLESCENT; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; HUMAN; MEDICAL RESEARCH; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; SAMPLING; STEM CELL TRANSPLANTATION; THALASSEMIA;

ADOLESCENT; AREA UNDER CURVE; BAYES THEOREM; BUSULFAN; CHILD; CHILD, PRESCHOOL; HALF-LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INJECTIONS, INTRAVENOUS; MYELODYSPLASTIC SYNDROMES; THALASSEMIA; TRANSPLANTATION CONDITIONING;

EID: 0036223959     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01555.x     Document Type: Article

References (13)

1. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
2. Busulfan disposition in children
3. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
4. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
5. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
6. Busulphan pharmacokinetics and limited sampling model in children with leukemia and inherited disorders
7. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation
8. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
9. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
10. Pharmacokinetics of liposomal busulphan in man
11. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples
12. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies